InvestorsHub Logo
Post# of 253159
Next 10
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 190849

Sunday, 05/17/2015 4:30:03 PM

Sunday, May 17, 2015 4:30:03 PM

Post# of 253159
MNTA ReadMeFirst

[Updates:
Necuparanib abstract from ASCO 2015;
FDA guidance documents pertaining to FoBs;
2015-2016 news flow.]




CORPORATE AND FINANCIAL

What is MNTA’s business all about?
#msg-113297958 Transcript and notes from 1Q15 CC
#msg-107107809 Transcript /slide set from 10/10/14 R&D Day
#msg-49883723 MNTA is a beneficiary of US FoB legislation
#msg-26837144 Momenta’s mantra on biogenerics


News flow
#msg-113750966 2015-2016 possible/probable events


Valuation and finances
#msg-113313146 Current pro forma cash balance ~$237M
#msg-113313190 Diluted share count for valuation purposes
#msg-112962661 SEC filing for new $75M ATM financing vehicle
#msg-113297958 MNTA’s model of Glatopa’s addressable market
#msg-113005592 Glatopa milestone payments from NVS
#msg-112813558 Future of 40mg Copaxone formulation key to MNTA’s valuation
#msg-106946415 MNTA’s NOLs
#msg-112887285 Musings on buyout vig


Management, BoD, and major shareholders
#msg-113006744 Composition of Board of Directors
#msg-113006370 Insider shareholdings and options
#msg-113147094 Major shareholders

#msg-94898356 Michael Franken named head of FoB program (12/13)
#msg-58383722 Young Kwon named VP, Business Development (1/11)
#msg-33979910 James Sulat named Chairman of BoD (12/08)
#msg-27338039 James Roach, CMO, joins MNTA (2/08)
#msg-12824293 Craig Wheeler, CEO, joins MNTA from Chiron (8/06)



COPAXONE PROGRAM

Economic rationale and profit split
#msg-113297958 MNTA’s model of Glatopa’s addressable market
#msg-113300123 MNTA guides to $35K revenue per Glatopa patient-year
#msg-12222305 NVS/MNTA split Glatopa profits 50/50
#msg-113234361 1Q15 US Copaxone sales were $732M
#msg-113005592 Glatopa milestone payments from NVS
#msg-110133704 Launch temporarily delayed while CAFC revisits ‘808 patent
#msg-112813558 Future of 40mg Copaxone formulation key to MNTA’s valuation


FDA approval of Glatopa
#msg-112799454 FDA approves Glatopa (generic Copaxone)
#msg-112799896 FDA rationale for approval
#msg-112812696 FDA not providing roadmap for other would-be generics
#msg-105740021 FDA accepts MNTA’s ANDA for 40mg Copaxone formulation


Potential competition from other generic Copaxone products
#msg-112887376 MNTA’s Copaxone IP may hold up against Safe Harbor challenge
#msg-112817624 Musings on likelihood of competition from other generics (MTB)
#msg-112848073 Musings on likelihood of competition from other generics (indigokid)

#msg-29902618 Mylan inks Copaxone deal with India’s Natco (Jun 2008)
#msg-41441618 FDA accepts Mylan’s Copaxone ANDA for review (Sep 2009)
#msg-90636221 Mylan and MNTA products are not identical
#msg-95940872 Musings on Mylan’s Copaxone ANDA from JPM 2014
#msg-70039774 Synthon submits Copaxone ANDA (Dec 2011)…
#msg-99675480 …but acknowledges receiving an unresolved CRL



FOLLOW-ON BIOLOGICS (FoB) PROGRAM

#msg-104501563 FoBs will be $35B market by 2020, says market consultant
#msg-104534644 More color on $35B forecast for 2020

#msg-70212854 MNTA inks FoB partnership with BAX
#msg-72624576 Redacted version of BAX-MNTA contract
#msg-110925786 BAX terminates collaboration for compounds other than Humira
#msg-111045283 Rationale for BAX decision

#msg-107076513 Lead FoB compound confirmed to be Humira
#msg-108636687 Humira FoB begins phase-1 in Europe.
#msg-97088208 Rationale for starting Humira Fob in Europe
#msg-70237561 An interchangeable Humira FoB has colossal upside
#msg-79941294 Survey of rheumatologists is (paradoxically) bullish for MNTA
#msg-107107809 MNTA’s FoB pipeline includes Orencia & several other compounds

#msg-48581353 Affordable Care Act (ObamaCare) enables US FoBs
#msg-113503321 FDA guidance documents pertaining to FoBs.
#msg-26837144 Momenta’s mantra on biogenerics
#msg-70191760 US patent-expiration dates of big-selling biologics



NECUPARANIB PROGRAM

#msg-37030489 Rationale for a heparin-derived cancer drug
#msg-108636891 Necuparanib receives FDA Fast Track designation
#msg-102765888 Necuparanib receives FDA Orphan Drug designation
#msg-113635463 Necuparanib abstract from ASCO 2015
#msg-87859870 Clinicaltrials.gov listing for Necuparanib phase-1/2 trial
#msg-107107809 Necuparanib phase-1 data (slides 31-35)
#msg-107107809 Necuparanib phase-2 design (slides 41-42)
#msg-107073252 Phase-2 powered at 80% for 50% increase in OS
#msg-107143382 Phase-2 trial has potential to be pivotal



ENHANCED-IVIG PROGRAM

#msg-111515491 What is IVIG? (short videos)
#msg-107107809 Structure & rationale for MNTA’s compound (slides 118-131)
#msg-101443478 MNTA reports preclinical data on IVIG program
#msg-69595597 MNTA acquires sialic switch IP from Virdante Pharmaceuticals
#msg-69681347 Musings on the Virdante deal
#msg-106041077 MNTA exercises Anaptys option



INTELLECTUAL PROPERTY

#msg-84501925 Musings on trade secrets and FDA disclosure policy
#msg-111389703 Recent patent applications and overview of IP estate
#msg-59682546 USPTO issues ‘187 patent re Copaxone manufacturing
#msg-112887376 MNTA’s Copaxone IP may hold up against Safe Harbor challenge
#msg-89344512 USPTO issues sialylation patent licensed to MNTA



PUBLICATIONS

#msg-86139857 FiercePharma re FoB manufacturing (3/13)
#msg-85017663 Boston Business Journal re FoB’s (2/13)
#msg-73905464 The Deal interviews Craig Wheeler re FoB’ (3/12)
#msg-66837147 NEJM on FoB pathway (9/11)
#msg-63126386 BioCentury re prospects for US FoB’s (5/11)
#msg-28748329 Nature Biotechnology re contaminated heparin (4/08)
#msg-23005127 Nature re FoB’s (9/07)
#msg-25803923 The Pink Sheet interviews Wheeler re MNTA’s technology (3/07)
#msg-25779774 Boston Globe re MNTA’s IPO (11/04)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.